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COST-EFFECTIVENESS OF RIOCIGUAT AND BOSENTAN FOR THE TREATMENT OF 
 
CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION 
 
AJIBADE OPEOLUWA ASHAYE 
 
ABSTRACT 
 
OBJECTIVE: To conduct a cost-effectiveness analysis of riociguat and bosentan in the 
management of chronic thromboembolic pulmonary hypertension (CTEPH) from a United 
States payer perspective. 
METHODS: A Markov model was developed following the recommendations of the 
International Society of Pharmacoeconomics and Outcomes Research - Society for 
Medical Decision Making Modeling Good Research Practices. A cohort of patients with 
inoperable CTEPH or post-pulmonary endarterectomy CTEPH were simulated over their 
lifetime. Health outcomes were measured as quality-adjusted life years (QALY). Efficacy 
and safety data were obtained from BENEFiT and CHEST-1 trials. Drugs costs, associated 
costs for the management of CTEPH, were obtained from Redbook and published 
information such as the Healthcare Cost and Utilization Project (HCUPnet) and Centers 
for Medicare & Medicaid Services Physician Fee Schedule. Deterministic and probabilistic 
sensitivity analyses were performed to assess the robustness of the model projections.  
RESULTS: Riociguat was more effective than bosentan with an incremental cost of 
$132,065 and an incremental quality-adjusted life year (QALY) of 0.20, corresponding to 
an incremental cost-effectiveness ratio (ICER) of -$649,380 per QALY (in favor of 
  vii 
riociguat). Riociguat had a lower total discounted lifetime cost compared to bosentan 
($2,307,488 versus $2,439,555). Probabilistic sensitivity analyses confirmed dominance 
of riociguat in 74% of the Monte Carlo simulations. 
CONCLUSIONS: Results of this model indicates that riociguat is more effective and less 
costly than bosentan in the management of patients with inoperable CTEPH or post-
pulmonary endarterectomy CTEPH.   
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BACKGROUND AND SIGNIFICANCE 
Chronic thromboembolic pulmonary hypertension (CTEPH) is a secondary form of 
pulmonary hypertension (PH), defined as an increased pulmonary arterial pressure 
(>25mm Hg) that is maintained for 6 months after diagnosis of a pulmonary embolism 
(PE) and is often accompanied by progressive right heart failure.1 The exact etiology of 
CTEPH is unclear, but the disease is believed to result from the formation of organized 
pulmonary artery obstructions after incomplete lysis of pulmonary thromboemboli in 
patients with venous thromboembolism.2,3 
Pulmonary endarterectomy (PEA) is the most effective treatment for CTEPH, with a 6-year 
survival rate of 75%.4 However, many patients are not candidates for PEA (due either to 
surgical inaccessibility of the lesions or to severe comorbidities)1 while others experience 
residual or recurrent PH after PEA.5 Until recently, no drug had been approved for treating 
CTEPH patients with inoperable disease or those with persistent disease post-PEA. 
Patients are often managed with targeted therapies for pulmonary arterial hypertension 
(PAH), mostly bosentan, an endothelin receptor antagonists (ERAs), considered to be the 
standard of care. Other off-label pharmacologic therapies include, phosphodiesterase-5 
(PDE5) inhibitors, and prostacyclin analogs.6 Riociguat, a soluble guanylate cyclase 
stimulator was approved by the United States (US) Food and Drug Administration and 
European Medicines Agency for the treatment of CTEPH in October 2013, and January 
2014 respectively. Its efficacy and safety was demonstrated in a Phase III, multicenter, 
randomized, double-blind, placebo-controlled trial.7 Findings from this trial suggest it is 
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more efficacious than the off-label bosentan previously considered the standard of care. 
However, this needs to be confirmed via indirect comparison due to the lack of head-to-
head trials. 
The objective of this project is to evaluate the cost-effectiveness of riociguat and 
bosentan in the management of inoperable CTEPH or post-PEA CTEPH in the US setting.  
This information is crucial as it provides physicians and other health care providers useful 
and relevant information needed to take informed decisions.  
RESEARCH QUESTION 
What is the comparative cost-effectiveness of riociguat and bosentan as pharmacological 
treatments for the management of inoperable CTEPH or post-PEA CTEPH? 
METHODOLOGY 
Overview 
The project utilized a mix of evidence-generation methods including a systematic 
literature review, an indirect treatment comparison analysis, as well as an economic 
analysis using the cost-effectiveness framework. Systematic literature reviews, especially 
of randomized controlled trials, are considered one of highest levels of evidence.8 They 
are particularly useful in identifying and generating comparative efficacy and safety 
evidence in the absence of evidence from head-to-head comparisons of interventions 
when combined with a meta-analysis.9 Searches for the systematic literature review were 
conducted in literature databases (MEDLINE via PubMed, Embase, and Cochrane Central 
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Register of Clinical Trials) for clinical trials of bosentan and riociguat in CTEPH patients. 
Efficacy, safety, and quality of life data were retrieved from identified articles (including 
the phase 3 trials of each treatment) and supplemented by additional literature. In the 
absence of head-to-head comparisons for the two treatments, Bayesian ITCs (fixed 
effects) was used to derive comparative efficacy and safety estimates. 
Economic evaluations, particularly cost-effectiveness analyses, are important in 
“identifying, measuring, valuing, and comparing the cost and consequences of two or 
more courses of action that have the alternative therapies for a specific indication”.10 
They are useful particularly in the settings of budget constraints that typifies many 
healthcare systems. The analysis is based on a Markov-cohort approach. Details of the 
methodologies are provided in subsequent sections of the document 
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Conceptual Model  
Figure 1. Influence Diagram  
 
 
 
Figure 2. Markov Model Health States Transitionsa  
 
 
  
                                                 
a Health States are based on the functional classification systems (the New York Heart Association 
Functional Classification/ World Health Organization Functional Assessment Classification)  
FC II FC III FC IV
Death
 5 
Table 1. New York Heart Association Functional Classification 
Class Symptoms 
Class I No symptoms with ordinary physical activity.  
Class II Symptoms with ordinary activity. Slight limitation of activity. 
Class III Symptoms with less than ordinary activity. Marked limitation of activity. 
Class IV Symptoms with any activity or even at rest. 
Adapted from Rubin LJ. Diagnosis and management of pulmonary arterial hypertension: ACCP 
Evidence-Based Clinical Practice Guidelines. Introduction. Chest. 2004; 126:7S–10S 
 
Table 2. World Health Organization Functional Assessment Classification 
Class Symptoms 
Class I Patients with PH but without resulting limitation of physical activity. Ordinary 
physical activity does not cause undue dyspnea or fatigue, chest pain, or near 
syncope. 
Class II Patients with PH resulting in slight limitation of physical activity. They are 
comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, 
chest pain, or near syncope. 
Class III Patients with PH resulting in marked limitation of physical activity. They are 
comfortable at rest. Less than ordinary activity causes undue dyspnea or fatigue, 
chest pain, or near syncope. 
Class IV Patients with PH with inability to carry out any physical activity without symptoms. 
These patients manifest signs of right-heart failure. Dyspnea and/or fatigue may 
even be present at rest. Discomfort is increased by any physical activity. 
Adapted from Rubin LJ. Diagnosis and management of pulmonary arterial hypertension: ACCP 
Evidence-Based Clinical Practice Guidelines. Introduction. Chest. 2004; 126:7S–10S 
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Systematic Literature Review Methods 
MEDLINE- (via PubMed), EMBASE-indexed literature published as of March 2016 were 
systematically reviewed to identify randomized controlled trials evaluating bosentan and 
riociguat. The review was limited to studies published in English. The search algorithm 
included a combination of medical subject headings (MeSH) terms and free-text terms for 
CTEPH and study designs of interest. The complete search strategy for each database can 
be found in Appendix A. 
Citations returned from the searches of the electronic databases were screened in two 
rounds. In the first round, identified titles/abstracts were screened using the predefined 
inclusion and exclusion criteria specified in Table 3. Titles/abstracts that could not be 
definitively excluded were accepted at this round and the full publication retrieved for 
further review. The second round of screening involved review of the full text of articles 
deemed relevant during the first round. 
In addition to identifying RCTs for the interventions being compared, references of 
existing systematic literature reviews and meta-analyses of bosentan and riociguat as it 
relates to the management of chronic thromboembolism were reviewed. The primary 
purpose of reviewing the references of these articles is to identify potentially relevant 
literature. 
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Table 3. Inclusion and Exclusion Criteria 
Inclusion Criteria 
Population Patients with CTEPH 
Intervention/Comparators Bosentan or riociguat 
Outcomes  Any efficacy, quality of life outcome, or safety outcome 
Study Design 
Randomized controlled trials (RCT) Phase II/III (including 
subgroup analyses and post-hoc analyses)   
Exclusion Criteria 
Population 
 
Studies of non-CTEPH patients 
Studies with mixed population where outcomes are not reported 
separately for the CTEPH population 
Intervention/ Comparators Studies that did not evaluate bosentan or riociguat  
Outcomes  Studies lacking relevant data on any of the outcomes of interest 
Study Design 
Narrative reviews, guidelines, commentary, letters to the editor, 
conference proceedings, no abstract to inform decision (for 
conference abstracts) 
Animal or in vitro studies 
Pharmacokinetic or pharmacodynamic studies 
Abbreviations: CTEPH=Chronic thromboembolic pulmonary hypertension  
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Indirect Treatment Comparison Methods 
Assessing feasibility of Indirect Treatment Comparison 
Prior to conducting the indirect treatment comparison (ITC), the relevant trials were 
assessed to determine if they can be connected in an evidence network. The following 
elements were reviewed to determine if the trials are sufficiently similar, or if any 
dissimilarity are serious enough to preclude an indirect comparison. 
● Comparability of patient populations, and confounding factors in relation to the 
patient population  
● Similarity of treatments (including background and/or concomitant treatments) 
● Differences in the definition, measurement and reporting of outcomes 
● Study design, including the quality of methods employed in the trial 
Once a connected network was established, the extent of clinical heterogeneity based 
on key elements of the two trials were then reviewed and assessed.  
Overview of the Bayesian Algebraic Model  
In the absence of direct, head-to-head evidence comparing treatments A and B (e.g., a 
log-odds ratio [LOR] or a mean difference [MD] between treatments; call this comparison 
dAB), an unbiased estimate from RCTs comparing treatments A and C and from RCTs 
comparing B and C can be derived11: 
dAB = dAC - dBC    (Equation 1) 
The assumption being made is that the same dAB that is estimated by the AB trials would 
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be estimated in the BC and AC trials, only if all three treatments had been included in 
them. If this assumption is correct, indirect evidence can be used not only instead of 
direct evidence, but also to supplement it.  
Consider a hypothetical situation with four treatments (A, B, C, and D) investigated in 
several pairwise trials. Functional parameters dBC, dBD, and dCD can then be expressed in 
terms of the basic parameters dAB, dAC, and dAD:  
dBC = dAC - dAB 
dBD = dAD - dAB     (Equation 2) 
dCD = dAD - dAC  
For the purposes of this example, assume the outcome is binary in nature (e.g. treatment 
discontinuations), although similar logic applies for continuous outcomes. The data 
consist of the numerators rjk (numbers successfully treated) and denominators njk for 
trials j=1,2… and treatments k = A,B,C,D. If we take pjk as the probability of success on 
treatment k in trial j, then the numerators rjk come from a binomial distribution with 
denominators njk and probabilities pjk. The likelihood contribution of each arm is thus: 
rjk ~ Bin (pjk, njk)     (Equation 3) 
The role of the model is to relate the probabilities pjk to the basic parameters, if 
necessary, via the functional parameters. The RE model can be expressed in the form of 
a logistic regression (Equation 4): 
Logit (pjk) =  μjb  if k=b, b=A, B, C 
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μjb + δjbk if k alphabetically “after” b  (Equation 4) 
Where μjb represents the LOR of success for treatment b in study j and δjXY—the LOR for 
treatment Y relative to treatment X in trial j—is drawn from a normal distribution, δjXY~ 
N(dXY, σ2), with a mean dXY and variance σ2 to be calculated from the data.  
The formulas for continuous outcomes are simpler, using an identity link instead of a 
logit link. Let λjk represent the observed mean change in the outcome on treatment k in 
trial j, with variance σ jk.12,13 
λ jk ~ (θjk, σ jk)     (Equation 5) 
θjk =  μjb  if k=b, b=A, B, C 
μjb + δjbk  if k alphabetically “after” b (Equation 6) 
For comparison-level data (e.g., log-hazard ratios), the logic is similar, and an identity link 
is also employed.13 Thus, this procedure allows the estimation of relative effectiveness 
(in the form of log-odds or log-hazard ratios) of each pair of treatments. It also allows for 
the estimation of the underlying probabilities of events for individual treatments (pk), or 
a similar treatment-specific statistic in the case of other outcomes. While all analyses 
will, as noted above, either be based in log-odds due to the logit link, or utilize log-hazard 
ratios as inputs, all outputs were in terms of odds ratios and mean differences.  
All Bayesian indirect treatment comparison (ITC) analyses involved a 50,000-run-in 
iteration phase and a 50,000-iteration phase for parameter estimation. Analyses were 
conducted using OpenBUGS v3.2.2 and R3.3.0.  
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Model Convergence 
Convergence was confirmed by inspection of the ratios of Monte Carlo error to the 
standard deviations of the posteriors (<5% generally implies adequate convergence) and 
examinations of the three-chain Brooks-Gelman-Rubin (BGR) plots.14,15   
Investigation of Statistical Heterogeneity 
Statistical heterogeneity is defined as the instance where a set of true relative treatment 
effects varies across studies; in other words, the observed treatment effects vary more 
than would be expected due to sampling error. Statistical heterogeneity between the 
same comparisons are typically evaluated using the I-squared (I2) statistic, which 
describes the percentage of total variation across studies that is due to heterogeneity 
rather than chance. A value of 0% indicates no observed heterogeneity, and larger values 
show increasing heterogeneity. Typically, I2 values of 25%, 50%, and 75% are considered 
low, moderate, and high.16 Only two RCTs (one for each intervention of interest) form 
the evidence network for the analyses, hence investigation of statistical heterogeneity 
using the I-squared statistics was not applicable.  
Consistency 
Consistency is defined as an agreement between direct and indirect sources of evidence. 
In the evidence networks, there are no instances of a comparison benefiting from both 
direct and indirect evidence. Subsequently, it is not possible to assess inconsistency.16–18 
Statistical Models 
A fixed-effects (FE) indirect treatment comparison model19–22 was conducted to generate 
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comparative effectiveness and safety estimates using data from the RCTs of each 
intervention of interest (bosentan and riociguat). Fixed-effects models assumes that 
“there is no variation in relative treatment effects across studies for a particular pairwise 
comparison; and any difference is due to sampling error”.23  
Random-effects (RE) models on the other hand, assumes that the “true relative effects 
across studies are exchangeable (i.e., the prior position of expecting underlying effects 
to be similar but not identical) and can be described as a sample from a normal 
distribution whose mean is the pooled relative effect and whose standard deviation 
reflects the heterogeneity.23,24 RE models are not appropriate in this case due to the 
nature of the network and the lack of adequate data to estimate a random-effects 
variance (network with only two trials, one for each intervention of interest).12,23,24 
Cost-Effectiveness Model Methods  
Overview 
The economic evaluation is based on a Markov model which follows the 
recommendations of the International Society of Pharmacoeconomics and Outcomes 
Research - Society for Medical Decision Making Modeling Good Research Practices. Costs 
and health benefits were discounted at 3.5% annual rate.25 Sensitivity analyses were 
performed as appropriate. The model was programmed in TreeAge® Pro Software 2011. 
Markov models (or State Transition Models [STMs]) are one of the common models used 
in economic evaluations. This approach frames decision problems in terms of distinct, 
mutually exclusive health states, and conceptualizes the transition of patients among 
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these states during fixed intervals in time. In addition, “it assumes the interactions 
between individuals are not relevant, and the population of interest is a closed cohort”.26 
The main advantage of this approach is its simplicity, the ease of analyses and 
communication using user-friendly software such as TreeAge® or Microsoft Excel®. 
However, it does not have the flexibility required to respond to the broad variations in 
the patient population and is limited by the Markov assumption of no memory. Details 
of the model elements are presented below. 
Population 
The population of interest are patients with inoperable CTEPH or with persistent or 
recurrent pulmonary hypertension following pulmonary endarterectomy.  
Comparators 
The model evaluated the cost-effectiveness of riociguat monotherapy compared to 
bosentan monotherapy. 
Setting 
The cost-effectiveness analysis is based on the US market and conducted from the 
economic perspective of the government payer. Therefore, only direct costs are 
assessed.  
Time Horizon 
The model projects costs and outcomes up to the patient lifetime (assumed to be a 
maximum of 41 years or death). The time horizon is broken into four-month cycles to 
correspond to the duration of the CHEST-1 trial,7 the primary source of data, and to 
 14 
enable changes in patient health status and resource use to be captured. 
Discount Rate and Currency Year 
Discounting adjusts current costs and benefits to be worth more than those occurring in 
the future because the assumption is that there is an opportunity cost to spending 
money now instead of later. Costs and health benefits are discounted at 3.5% annual 
rate. Currency year is 2016 US dollars. 
Model Outcomes 
The model collects the following health outcomes: QALYs, and costs. The ICER, which is 
the incremental cost per QALY gained, is regarded as the primary cost-effectiveness 
outcome measure in health economics. This measure reflects the cost to gain each 
additional QALY when using riociguat versus bosentan.  
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Model Diagram 
A diagram showing the decision nodes and Markov health states is shown below  
Figure 3. TreeAge Model Diagram 
 
 16 
Model Inputs 
Mortality 
Data on mortality included in the model were based on the primary trial publications for 
each intervention, as well as age- and gender-specific background mortality derived from 
the United States Life Tables 2013.27 The mortality rates were then converted to a 
probability using well-established methods.28,29  
 Converting probability to rates: 
− ln(1−𝑝)
𝑡
 
 Converting rates to probabilities: 1 − 𝑒𝑥𝑝(−𝑟𝑡) 
Where p is the probability, t is time, and r is rate.  
Functional class-specific mortality rates were not identified in the literature, and were 
not included in the model. The combined mortality rate for the overall population was 
used. Of note, mortality rates were not significantly different between riociguat and 
bosentan compared to placebo/standard of care in the primary trials,7,30,31 or in the 
indirect treatment comparison, as such the relative mortality rates between riociguat 
and bosentan were not applied in the model.  
Adverse Events 
Adverse event (AEs) rates for riociguat and bosentan were identified from their 
respective phase III trials and the product labels.7,30,31 Only the most relevant AE for each 
intervention were included in the model, specifically liver toxicity. No data on disutilities 
were identified, hence they were not considered in the model. Disutilities are likely to 
already be accounted for in the data capturing utilities by FC. (Table 12  and Table 13) 
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Treatment Discontinuation 
Discontinuation rates for riociguat and bosentan were identified from the CHEST-1 trial 
and BENEFiT study respectively (See table below). The overall discontinuation rate was 
not significantly different between both treatments based on the ITC (Table 15), hence 
this variable was not included in the model.  
Table 4. Treatment Discontinuation Rate and Adverse Event Rate 
Parameter Riociguat Bosentan Source 
Discontinuation Rate (Mean, SD) 1.2%, 0.12% 3.00%, 0.30% 
CHEST-1 Trial7 
BENEFiT Trial30 
Liver Function Abnormalities 0% 7% 
Costs and Resources Use  
Costs used in the model were derived from a mix of sources – public, as well as 
subscription-based sources like RedBook32 and adjusted to 2016 US dollars where 
applicable. A micro-costing approach was used.25  
Table 5. Treatment Dosing and Cost 
Drug  Dosage 
Cost/Day 
Cost/month 
Source 
Riociguat Initiate treatment at 1 mg taken three times a day. 
Increase dosage by 0.5 mg at intervals of no sooner 
than 2-weeks as tolerated to a maximum of 2.5 mg 
t.i.d33b 
$231.46 
$6,943.86 
Red Book32 
Bosentan 125mg b.i.d or 250mg total31 $184.98 
$5,549.40 
Red Book32 
In addition to the active interventions, CTEPH patients receive supportive care which 
                                                 
b The 2.5mg dose was assumed.  
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could include supplemental oxygen, warfarin, furosemide, and digoxin. Details of the 
associated costs are provided below.  
Table 6. Supportive Care - Oxygen 
Drug  Volume  Cost per 3 months Data Source 
Oxygen 26% across all functional classes.c   DMEPOS Fee 
Schedule July 2013 
File Uptake FC II: 6% $332.3 
Uptake FC III: 30% $332.3 
Uptake FC IV: 63% $332.3 
 
Table 7. Other Supportive Care – warfarin, furosemide, digoxin 
Drug Volume 
% of patients 
receiving 
Cost/Day, Cost/month Data Source 
Warfarin 5 mg/day 27.57% $0.66860, $20.06 Red Book32 
Furosemide 100 mg/day 55.07% $0.715, $21.45 Red Book32 
Digoxin 125 mcg/day 11.92% $1.42200, $42.66 Red Book32 
Other costs and resource use associated with the management of CTEPH are noted in 
the tables below. They include liver function test (for patients on bosentan), and costs 
of routine care by FC [comprising hospitalization, visits to specialist and primary care 
physician, and diagnostic testing]. The annual rates of accessing these resources were 
obtained from an European study by Schweikert et al 201434 in the absence of US data.  
                                                 
c 1,360 litres/day for FCI-III. 2,122 litres/day for FC IV 
 19 
Table 8. Laboratory Tests  
 Liver Function Test Total Costs USD 
Riociguat 0 $0 
Bosentan 1 $11.13 
 
Table 9. Routine Care by FC 
FC 
Cost per 
Month 
Data Source 
FC II $0 NICE PAH Assessment Report 2007  
FC III  $304.8 NICE PAH Assessment Report 2007  
FC IV $709.4 NICE PAH Assessment Report 2007  
 
A micro-costing approach was used to estimate costs, hence the aggregate routine care cost 
data identified from the literature were not used in the model. 
Table 10. Ongoing Resource Use 
Resource  Mean ± SD Median Source  
Hospitalizations/year 1.8 ± 2.2 1.0 
Schweikert 2014,34 EU 
data 
Hospitalization days/year 14.8 ± 26.1 7.8 
Specialist visits/year 1.3 ± 1.4 0.9 
Primary Care Doctor visits/year 2.8 ± 4.2 0.7 
Diagnostic tests/year 8.4 ± 5.9 7.8 
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Table 11. Unit Costs for Resource Use  
Resource Unit Cost USD Source 
Average length of 
stay 
Mean: 6.5 days, SE: 0.262 
Median: 4.0 days 
ICD 9 code: 416.8 Healthcare 
Cost and 
Utilization 
Project 
(H.CUPnet)35 
 
Hospitalization – per 
Episode 
Mean charges: $70,139, SE $5,532 
Median charges: $34,414 
Mean costs:  $19,216, SE $1,764 
Median costs new: $9,479 
ICD 9 code: 416.8 
Specialist Nurse/PAs 99201 – 1st visit 
Non-facility limiting charge: $48.11 
99201 – other visits (same as 1st visit) 
Centers for 
Medicare & 
Medicaid 
Services 
Physician Fee 
Schedule36 
 
Visit to Primary Care 
Doctor 
99202 – 1st visit 
Non-facility limiting charge: $82.14 
99212 – other visits 
Non-facility limiting charge: $47.72 
Visit to Specialist - 
Pulmonologist 
99204 – 1st visit 
Non-facility limiting charge: $181.50 
99214 – other visits 
Non-facility limiting charge: $118.13 
ECG $55.94 HCPSC Code: 93005 
Current 
Procedural 
Terminology, 
Fourth Edition 
("CPT®"), 
Addendum B, 
July 201637 
VQ Scan $441.36 HCPSC Code: 78582 
CT Scan Thorax $112 [HCPSC Code: 712500 w/o dye] 
$236.86 [HCPSC Code: 71260 with] 
$347.72 [HCPSC Code: 71270 with or w/o dye] 
CT - Pulmonary 
Angiogram of the 
Chest 
$236.86 HCPSC Code: 71275 
Liver Function Test $11.13 HCPSC Code: 80076 
The charge-to-cost conversion was not necessary since costs were available in the HCUP 
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data source. The mean cost for hospitalization per episode was used in the model.  
Utilities 
Quality of life data were estimated based on the EuroQol-5D (EQ-5D) baseline scores 
reported in the CHEST-I study, adjusted based on other values identified from the 
literature. (see Table 12 and Table 13 below).  
Table 12. Utilities from EQ-5D 
Functional Class  Mean, SD Source  
FC II 0.72, 0.21 
A combination of CHEST-1 
trial7 and other sources noted 
in Table 13 below 
FC III 0.64, 0.26 
FC IV 0.41, 0.26 
 
Estimates of utilities by FC from other published studies were also identified, although 
these were specific to PAH and not CTEPH. 
Table 13. Additional Utilities by FC Values from Published Studies  
Functional class Keogh 200738 
Kirsch 200039 
2 year 
Kirsch 200039 
10 year 
Olschewski 
200240 
FC II 0.67, 0.10 0.78, 0.031 0.76, 0.023 0.75, 0.193 
FC III 0.60, 0.10 0.55, 0.045 0.50, 0.044 0.61, 0.254 
FC IV 0.52, 0.09 0.37, 0.051 0.28, 0.051 0.44, 0.291 
Values are mean, SD 
Efficacy of Treatment 
Transition probabilities for each intervention was derived by applying the relative effects 
from an indirect treatment comparison analyses,41 which estimated the comparative 
impact of bosentan and riociguat on the improvement and worsening in FC, to the 
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baseline probabilities for FC improvement and worsening with supportive care alone. 
Please note that the population for the analyses were subjects with PAH. These data 
were used in the absence of CTEPH-specific data.  
Subjects could remain in their starting functional class, improve (i.e. transition to a lower 
FC), or worsen (i.e., transition to a higher FC) during a treatment cycle. Subjects were 
only allowed to move one FC at a time. I assumed that interventions resulted in 
improvements in FC during the first cycle. This assumption is based on the lack of long-
term data and on the fact that the impact of each intervention on FC change were 
evaluated in the primary trials during the 12- to 16-week study duration. Evidence from 
the trial publications also indicate that the interventions reduces the risk of FC 
worsening.7,30 Transition probabilities used in the model were identified from an indirect 
treatment comparison41 mentioned earlier in this section, and are noted below:  
Supportive care  
 Probability of FC improvement: 0.10  
 Probability of FC worsening: 0.12 
Relative risk of FC improvement versus supportive care (95% CrI) 
 Bosentan: 2.05 (1.25, 3.32) 
 Riociguat: 1.49 (0.90, 2.46) 
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Relative risk of FC worsening versus supportive care (95% CrI) 
 Bosentan: 0.46 (0.18, 1.04) 
 Riociguat: 0.22 (0.07, 0.63) 
Sensitivity Analysis 
Sensitivity analyses were conducted to qualify and quantify the uncertainty surrounding 
some of the model parameters.42 Deterministic (one-way) sensitivity analyses were 
conducted by systematically varying model parameters one at a time.  A probabilistic 
sensitivity analysis was also conducted to account for multivariate and stochastic 
uncertainty in the model. The uncertainty in the individual parameters were 
characterized by using the appropriate distributions for certain model parameters.  The 
probabilistic sensitivity analysis was conducted as a sampling Monte Carlo simulation in 
Treeage with 100,000 replications. 
The following distributions were applied: 
 Costs: Gamma distribution 
 Transition probabilities and utilities: Beta distribution 
 Relative risk of worsening or improving: Log –normal distribution 
Table 23 summarizes additional information on the variables, and distributions included 
in the PSA. 
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RESULTS  
Systematic Literature Review 
The MEDLINE (via PubMed), EMBASE, and CENTRAL searches yielded a total of 128 
records (25 from MEDLINE, 72 from EMBASE, and 31 from CENTRAL), with some overlap 
between the databases. After removing duplicate articles, 95 unique records were 
identified and screened, of which 41 were selected for further review in the full text. 
Ultimately 12 records were identified as relevant (list provided below). A diagram 
summarizing the flow and attrition of records identified from the database searches 
through the two stages of screening is presented in Appendix B. A list of articles 
identified from the literature review is presented below. 
1. Confalonieri M, Vassallo FG, Scarduelli C, et al. A preliminary open label controlled 
trial with bosentan in patients affected by chronic thromboembolic pulmonary 
hypertension (CTEPH) [Abstract]. Proceedings of the American Thoracic Society. 
2006:A167 [Poster D169].  
2. D'Armini AM, Ghofrani HA, Kim NH, Mayer E, Simonneau G, Wilkins MR. Riociguat for 
the treatment of inoperable CTEPH or persistent/recurrent PH after pulmonary 
endarterectomy (PEA): A responder analysis from the phase III CHEST-1 study 
[Abstract]. European Respiratory Society Annual Congress, 2013 Sept 7–11, 
Barcelona, Spain. 2013;42(Suppl 57):543s [P2598].  
3. Ghofrani H, Grimminger F, Hoeper M, et al. Riociguat for the treatment of inoperable 
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chronic thromboembolic pulmonary hypertension: A randomized, double-blind, 
placebo-controlled study (CHEST-1). Chest. 2012;142(4). 
4. Ghofrani HA, D'Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic 
thromboembolic pulmonary hypertension. New England Journal of Medicine. 
2013;369(4):319–329. 
5. Ghofrani HA, Grimminger F, Hoeper MM, et al. Impact of riociguat on health-related 
quality of life (HRQoL) in patients with chronic thromboembolic pulmonary 
hypertension (CTEPH). European Respiratory Journal. 2013;42. 
6. Jais X, D'Armini AM, Jansa P, et al. Bosentan for treatment of inoperable chronic 
thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable 
Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, 
placebo-controlled trial. Journal of the American College of Cardiology. 
2008;52(25):2127–2134. 
7. Jais X, Ghofrani A, Hoeper MM, Lang I, Mayer E, Pepke-Zaba J. Bosentan for 
inoperable chronic thromboembolic pulmonary hypertension (CTEPH): a 
randomized, placebo-controlled trial - BENEFIT [Abstract]. American Thoracic Society 
International Conference, May 18–23, 2007, San Francisco, California, USA. 2007: 
Poster #D82.  
8. Jansa P, Ghofrani HA, Hoeper MM, et al. Comparison of hemodynamic parameters in 
patients with inoperable and persistent/recurrent chronic thromboembolic 
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pulmonary hypertension (CTEPH) in the Phase III CHEST-1 study. European Heart 
Journal. 2013;34:187. 
9. Kim NH, D'Armini A, Grunig E, et al. Hemodynamic assessment of patients with 
inoperable chronic thromboembolic pulmonary hypertension (CTEPH) in the phase 
iii chest-1 study. American Journal of Respiratory and Critical Care Medicine. 
2013;187. 
10. Lang IM. Bosentan for inoperable chronic thromboembolic pulmonary hypertension 
(CTEPH) and post -pulmonary endarterectomy pulmonary hypertension: a subgroup 
analysis of the randomized, placebo-controlled trial - BENEFiT. Clinical research in 
cardiology. 2007;96(11):779–780.  
11. Mayer E, D'Armini AM, Ghofrani HA, et al. Efficacy of riociguat in patients with 
inoperable CTEPH vs persistent/recurrent PH after pulmonary endarterectomy (PEA): 
Results from the phase III CHEST-1 study. European Respiratory Journal. 2013;42. 
12. Papke-Zaba J, Mayer E, Simmoneau G, Rubin LJ, Lang I, Hoeper MM. Bosentan for 
inoperable chronic thromboembolic pulmonary hypertension: a randomised, 
placebo-controlled trial - BENEFiT [Abstract]. Thorax. 2007;62(Suppl iii):A15.  
Evidence Network  
The evidence network consists of two randomized controlled trials, BENEFiT (bosentan), 
and CHEST-1 (riociguat) identified from the systematic literature review. 
The BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic 
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pulmonary hypertension) was a 16-week, phase 3, double-blind, randomized, placebo-
controlled study investigating the efficacy and safety of bosentan in patients with chronic 
thromboembolic pulmonary hypertension who were considered either inoperable or 
had persistent/recurrent pulmonary hypertension after pulmonary endarterectomy (≥6 
months after PEA).30 
Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase–
Stimulator Trial 1 (CHEST-1) is a 16-week, phase 3, double-blind, multicenter, 
randomized, placebo-controlled study investigating the efficacy and safety of riociguat 
in patients with chronic thromboembolic pulmonary hypertension who were considered 
by experienced surgeons to be ineligible for surgery or who had persistent or recurrent 
pulmonary hypertension after pulmonary endarterectomy.7 
The network formed from these two trials are shown below. Placebo is acting as a 
common comparator for both treatments. 
Figure 4. Evidence Network of Trials 
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Table 14. Characteristics and Findings of CHEST-1 and BENEFiT Trials 
 BENEFit CHEST-1 
 Placebo 
n=80 
Bosentan 
n=77 
Placebo 
n=88 
Riociguat 
n=173 
Baseline Characteristics     
Age (yrs)* 63.1 ± 10.3 63.0 ± 12.9 59 ± 13 59 ± 14 
Females, % 58.8 71.4 61 68 
PVR (dyn·s·cm-5)* 787 ± 333 778 ± 323 779 ± 401 791 ± 432 
6MWD (m)* 344.5 ± 82.6 340.0 ± 85.3 356 ± 75 342 ± 82 
WHO FC (I/II/III/IV) 0/22/56/2 0/22/51/3 0/25/60/2 3/55/107/8 
mPAP (mmHg)* 47.4 ± 12.5 44.2 ± 10.4 44 ± 10 45 ± 13 
mRAP (mmHg)*  8.4 ± 6.0 8.3 ± 6.1 9 ± 6 9 ± 5 
BDI* 4.1 ± 2.3 4.4 ± 2.0 4.0 ± 2.0 4.0 ± 2.0 
NT-proBNP (ng/l)* 1405 ± 1882 1481 ± 1833 1706 ± 2567 1508 ± 2388 
Outcomes at 12/16 weeks  
6MWD change (m) 0.8 (-18.1,  19.7)# 2.9 (-12.9, 18.8)# -6 ± 84 39 ± 79 
WHO FC  9 improved 
64 no change 
7 worsened 
11 improved 
64 no change 
2 worsened 
13 improved 
68 no change  
6 worsened 
57 improved 
107 no change  
9 worsened 
BDI change 0.2 (-0.3, 0.6)# -0.4 (-0.8, 0.0)# 0.2 ± 2.4 -0.8 ± 2  
PVR change (dyn·s·cm-5) 30 (-25, 85)# -146 (-207, –85)# 23 ± 274 -226 ± 248  
NT-proBNP (ng/l)## -622 (-1018, -225), 0.0034 -444 (-843, -45), <0.001 
mRAP (mmHg)## -0.8 (-2.6, 1.0), 0.6277 -0.6 (-1.7, 0.6), 0.4 
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 BENEFit CHEST-1 
 Placebo 
n=80 
Bosentan 
n=77 
Placebo 
n=88 
Riociguat 
n=173 
mPAP (mmHg)## -2.5 (-5.0, 0.0), 0.0652 -5 (-7, -3), <0.001 
Safety, n (%)    
Clinical worsening 5 (6.3) 3 (3.9) 5 (6) 4 (2) 
Elevated LFTs >3 ULN 3 (3.8) 11 (14.5) 0 0 
Death 1 (1) 1 (1) 3 (3) 2 (1) 
Headache (1.3) (6.5) 12 (14) 43 (25) 
Abbreviations: mPAP=mean pulmonary artery pressure; mRAP=mean right atrial pressure; NT-
proBNP=N-terminal pro-brain natriuretic peptide; PEA=pulmonary endarterectomy; 
PVR=pulmonary vascular resistance; SD=standard deviation; TPR=total pulmonary resistance; 
WHO=World Health Organization. 
*Mean ± SD; # n (95% confidence interval); ## Mean treatment effects (95% confidence interval) 
 
Indirect treatment Comparison Analyses 
Results of the Bayesian fixed-effects ITC analyses are shown below.  
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Table 15. Summary of Indirect Treatment Comparison Results  
 Effect Measure Estimate (95% CrI) 
Primary Analyses   Riociguat vs. Bosentan 
Efficacy Outcomes   
Change in 6MWD Mean Difference 42.2 (9.8, 74.8)¥ 
Change in NT proBNP (pg/mL) Mean Difference 242.8 (-238.9, 725) 
Change in PVR (dyn*sec*cm-5) Mean Difference -72.9 (-181.3, 36) 
Change in Borg CR 10 Scale score  Mean Difference -0.4 (-1.3, 0.5) 
Odds of being in WHO FC II or better vs. FC 
III/worse 
Odds Ratio 1.15 (0.51, 2.61) 
Safety Outcomes    
Headache Odds Ratio 0.31 (0.01, 2.69) 
Hepatic Abnormalities  Odds Ratio 0.04 (0.00, 0.94)¥ 
Any AEs Odds Ratio 0.83 (0.27, 2.45) 
Discontinuations due to AEs Odds Ratio 3.24 (0.28, 58.03) 
Mortality Odds Ratio 0.29 (0.00, 18.43) 
Subgroup Analyses    
Inoperable CTEPH   
Change in 6MWD Mean Difference 43.5 (1.4, 85.6)¥ 
Change in PVR  Mean Difference -156.3 (-293.6, -19.6)¥ 
Post-PEA CTEPH   
Change in 6MWD Mean Difference 37.1 (-10.4, 84.3) 
Change in PVR  Mean Difference 131.5 (-34.9, 297.3) 
AE = adverse event; CTEPH = chronic thromboembolic pulmonary hypertension; FC = functional 
classification. ¥ Statistically conclusive result 
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There were statistical differences between riociguat and bosentan with regards to 
change in 6MWD and occurrence of hepatic abnormalities at 12–16 weeks in the overall 
population i.e. combination of subjects with inoperable disease and those with post-PEA 
CTEPH.  
In the subgroup analyses, treatment with riociguat led to significantly higher 
improvements in 6MWD, and significant reduction in PVR in subjects with inoperable 
CTEPH, compared to bosentan. Results for subjects with persistent or recurrent CTEPH 
post-PEA were not statistically different. 
Cost-Effectiveness Analyses 
Base Case Analyses 
These analyses estimated the outcomes for a cohort of CTEPH patients receiving 
riociguat monotherapy or bosentan monotherapy over their lifetimes. Costs and 
outcomes were discounted by 3.5%.  
Model Assumptions 
All assumptions in the base-case analysis of the model are summarized in Table 16.   
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Table 16. Assumptions 
Domain Assumption Explanation/Implication 
Population A fixed cohort of patients 
was analyzed. 
1. Characteristic of Markov cohort 
models  
2. Incident CTEPH cases were not 
considered  
Treatment effect 
and 
haemodynamics 
Impact of hemodynamics 
was not included in the 
model. 
1. There is limited data showing the 
relationship between 
hemodynamics and health-
economic impact in pulmonary 
hypertension.  
2. It was difficult to justify the impact 
of haemodynamics on health-
economic outcomes based on 
available data.  
Transition 
probabilities  
Derived by combining the 
relative risk of FC 
improvement or worsening 
(on placebo/usual care) with 
the same sets of risks for 
riociguat and bosentan. Data 
from a surrogate disease 
(PAH) was applied in the 
absence of CTEPH-specific 
data 
1. CTEPH-specific data was not 
identified from the literature 
search 
2. Treatment effect may have been 
over- or underestimated. This 
impact is likely to be small 
considering there might be 
common mechanisms behind both 
diseases.  
Disutilities Not applied due to lack of 
evidence 
1. Disutility data on the specific AEs 
were not identified from the 
literature search 
2. Utility decrement associated with 
treatment may have been 
underestimated. Rates of adverse 
events were generally low and the 
utility decrement would have been 
marginal. As such, the impact of 
the underestimation is likely to be 
very small  
AE = adverse event; CTEPH = chronic thromboembolic pulmonary hypertension; FC = functional 
classification; RCT = randomized controlled trial, RR = relative risk 
Costs 
Costs associated with CTEPH for riociguat and bosentan are presented by drug costs, 
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supportive care costs, oxygen costs, and cost of LFTs (Table 17). Patients on bosentan 
had the highest discounted total life time cost at $2,439,555 per patient. The majority of 
this cost is made up of drug costs, $2,089,113. Total cost for riociguat was $2,307,489 of 
which $1,960,552 were drug cost.   
Table 17. Component of Costs for each Treatment Strategy 
Costs ($) Riociguat Bosentan 
Drug costs $1,960,552 $2,089,113 
Supportive care costs $12490 $12,490 
Oxygen costs $7,548 $8,988 
Follow-up costs (PCP + Pulmonologist) $10,311 $10,311 
Cost of LFT $0 $2,066 
Cost of Investigations $19,332 $19,332 
Cost of Hospitalization $297,255 $297,255 
Total $2,307,489 $2,439,555 
QALYs  
Heath outcomes are presented in terms of QALYs. As shown in Incremental Results 
Results are also presented as incremental gains in QALYS, costs and the ICERs, defined 
as the incremental average costs divided by the incremental total QALYs. Riociguat had 
the greatest impact on patient’s QoL due the marginally higher utility values associated 
with improved FC, compared to bosentan.   
Table 18, patients who received riociguat had the highest discounted QALYs over their 
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lifetime at 14.07 compared to 13.87 for bosentan. 
Incremental Results 
Results are also presented as incremental gains in QALYS, costs and the ICERs, defined 
as the incremental average costs divided by the incremental total QALYs. Riociguat had 
the greatest impact on patient’s QoL due the marginally higher utility values associated 
with improved FC, compared to bosentan.   
Table 18. Incremental Results (Costs, QALYs) and ICER 
  
LifeTime 
Costs 
Incremental 
Cost 
LifeTime 
Effectiveness QALYs 
Incremental 
QALYs ICER 
Bosentan $2,439,555 Reference 41.60 13.87 Reference Reference 
Riociguat $2,307,489 -$132,066 42.21 14.07 0.20 -$649,380 
ICER = incremental cost-effectiveness ratio; QALY = quality-adjusted life-year, Ref = reference 
Note: Lifetime effectiveness is converted to QALYs by dividing by 3. 
Deterministic Sensitivity Analysis  
The purpose of a deterministic sensitivity analysis is to identify parameters that could 
influence on model results. Results of the 1-way deterministic sensitivity analyses, 
including the base, low and high values used for each of the relevant variables, and the 
corresponding ICER values are shown in Table 19. Impact of variations in QALYs for each 
FC was not evaluated as they resulted in clinically implausible scenarios e.g. using a high 
input value for QALY of FC III such that the value becomes higher than that of FCII 
patients. 
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Table 19. Results of Deterministic Analysis for Riociguat versus Bosentan 
Parameter 
Main Case 
Input 
Value 
Low Input 
Value 
ICER from 
Low Input 
Value  
High Input 
Value 
ICER from 
High Input 
Value  
Discount Rate  3.5% 0 -$613,384 5% -$666,412 
Markdown for 
Drugs* 
1 0 -$17,236 0.5 -$333,308 
FC = Functional Classification; ICER = incremental cost-effectiveness ratio 
* applied only to riociguat and bosentan. Drugs used as supportive care (e.g. warfarin, digoxin) 
were not marked down 
Probabilistic Sensitivity Analysis 
The probabilistic analyses were run for 100,000 replications where values for specific 
variables were drawn repeatedly from a probability distributions specified a priori for 
select variables, specifically QALYs, probabilities for FC improvement or worsening, drug 
costs (bosentan, riociguat), and cost of hospitalization. The incremental cost-
effectiveness curves for riociguat compared to bosentan at a $50,000 and $100,000 per 
QALY gained thresholds are shown in Figure 5 and Figure 6 respectively.  As show in both 
figures, riociguat resulted in a more favorable ICER compared to bosentan in 74% of the 
Monte Carlo simulations (quadrant IV of the incremental cost-effectiveness plane). The 
remaining iterations (26%) where in quadrant III and mostly below the $50,000 or 
$100,000 WTP thresholds. 
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Figure 5. Incremental Cost-effectiveness for Riociguat vs. Bosentan, WTP $50,000  
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Figure 6. Incremental Cost-effectiveness for Riociguat vs. Bosentan, WTP $100,000  
 
 
The cost-effectiveness acceptability curve shown in Figure 7  is generated from the PSA 
and shows the likelihood of riociguat being cost-effective at various willingness to pay 
thresholds. Riociguat is cost-effective compared to bosentan at multiple willingness to 
pay thresholds ($50,000, $100,000, and $150,000) with the probability of it being cost-
effective decreasing as the WTP thresholds increases.  
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Figure 7. Cost-effectiveness Acceptability Curves for Riociguat versus Bosentan 
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DISCUSSION  
This Markov model was developed to evaluate the cost-effectiveness of pharmacologic 
therapies, riociguat and bosentan for inoperable or post-PEA CTEPH. The model 
calculates costs and outcomes associated with CTEPH over the lifetime of an average 59-
year-old American based on changes in FC. Riociguat emerged as the most attractive 
treatment strategy with a marginally higher QALY and lower life-time costs. The 
differences in life-time costs appear to the mostly driven by the additional costs of LFTs 
for patients on bosentan (bosentan is associated with elevations in LFTs) and the small 
difference in drug costs. Results of the ITC indicates that compared to bosentan, riociguat 
significantly improved 6-MWD, the primary outcome of the CHEST-1 and BENEFiT trials. 
There were no significant differences between both drugs with regards to hemodynamic 
parameters such as NT-proBNP, mPAP, and mRAP.  
A review of the literature for published studies evaluating the comparative cost-
effectiveness of riociguat and bosentan in CTEPH yielded four documents. One study was 
conducted in a US setting; the remaining three were conducted in a Canadian, Turkish, 
and Russian setting respectively. The US study was a Markov cohort-based cost-utility 
analyses from a US third-party payer perspective published as a meeting abstract. Details 
of the model such as time horizon, discount factors were not reported in the abstract. 
Authors reported  that riociguat was cost-effective at a threshold of $100,000/QALY after 
the first year of treatment, and it dominates bosentan by the second year of treatment 
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onwards – specific values were not reported.43 
The Turkish study was also reported as a meeting abstract. It evaluated the cost-
effectiveness of riociguat for inoperable or post-PEA CTEPH patients over life time (set 
at 30 years) from a Turkish payer’s perspective. Total cost (2014 dollars) of riociguat-
treated patients was $1,558 higher compared to bosentan; and riociguat was associated 
with increments of 1.0034 LYs compared to bosentan. The ICER of riociguat per LYs 
gained compared to bosentan was 6,750 USD. Riociguat was deemed cost-effective 
compared to bosentan with ICER values below the willingness-to-pay threshold (3-times 
GDP per capita ─ 32,346 USD) for Turkey.44 Similar to the first two studies, the Russian 
study was based on a Markov model. The difference in costs between riociguat and 
standard practice (comprised on bosentan monotherapy with addition of sildenafil 
therapy when patients progressed) was 60 646.15 RUB per patient per year in favor of 
the riociguat. Riociguat costs were lower in 94.4% of sensitivity analysis. Authors 
concluded that riociguat was more cost-effective.45 
The fourth study was documented in a Common Drug Review Pharmacoeconomic report 
developed by the Canadian Agency for Drug and Technologies in Health (CADTH) as part 
of its evaluation of the evidence submitted by riociguat’s manufacturer.46 This report 
documents a cost-utility analyses conducted from a Canadian Public Payer perspective 
over a lifetime (considered to be 20 years). Costs and health outcomes occurring one 
year post-treatment were discounted at an annual rate of 5% according to the CADTH 
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guidelines, and costs were reported in 2013 Canadian dollars. Riociguat dominated 
brand name bosentan – it had lower drug cost (–$58,409) and was more effective.  
One criticism noted by the CADTH was that the model was likely to have double counted 
the potential benefit of riociguat on mortality since it assumed that mortality increased 
by worsening FC, but mortality also increased by treatment (independent of FC status).  
Though conducted in different settings with different assumptions, findings from these 
studies indicate that riociguat is cost-effective compared to bosentan as a pharmacologic 
therapy for patients with inoperable CTEPH or post-PEA CTEPH. The findings align with 
the results of the current analyses.  
Riociguat is the only drug approved for the management of CTEPH, while bosentan is 
mostly used off-label. This impacts the ability of bosentan to compete on price. As time 
goes by, and in the absence of other approved agents, or approved agents that are most 
cost-effective, riociguat uptake may increase, and it will may become the standard of 
care. It will be interesting to see how the cost-effectiveness profile changes over time 
given the aforementioned. Given that CTEPH is considered a rare disease and that life 
expectancy for patients, particularly those in FC IV, may not exceed several years, the 
benefit of riociguat may be as a first-line pharmacologic therapy.  
There are some limitations to this economic model. Inputs for the model were sourced 
from published literature, using data specific to CTEPH where available. Data for a 
surrogate disease, PAH, was used in instances where CTEPH-specific data was 
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unavailable. Similarly, health care resource use data from the UK were used in the 
absence of US-specific data and model inputs where supplemented with assumptions as 
necessary.  This could have impacted the model outcomes although this impact is likely 
to be small. Use of CTEPH-specific data will be helpful to generate more robust results. 
However, the model provides some insight into the cost-effectiveness of riociguat, and 
the impact of uncertainties around specific model parameters on model predictions to 
be evaluated. Similarly, data from a well-conducted and appropriately powered direct 
head-to-head trial of riociguat and bosentan will provide less biased estimate of the 
relative efficacy and safety as compared to an indirect treatment comparison.  
A micro-costing approach was used for the cost inputs. Micro-costing is a cost estimation 
method that allows for precise assessment of the economic costs of health interventions. 
It is quite useful in deriving precise estimates of costs for interventions. However, it is 
not without drawbacks. For example, it is more complex and time consuming compared 
to other methods such as gross-costing or the use of aggregate costs identified from the 
published literature. Costs estimates calculated using micro-costing may not be 
generalizable to all settings (even within a country) due to other factors such as variation 
in discounts, or special price arrangements. 
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CONCLUSION 
Taken together, the results of the ITC and the economic evaluation indicate that riociguat 
monotherapy is a more effective and less costly pharmacologic therapy than bosentan 
monotherapy for the management of inoperable CTEPH or post-PEA CTEPH. 
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APPENDICES 
APPENDIX A. SEARCH ALGORITHMS FOR SYSTEMATIC LITERATURE REVIEW 
Table 20. MEDLINE via PubMed 
Search MEDLINE Search Algorithm Hits 
#1 CTEPH OR “Chronic thromboembolic pulmonary hypertension”  1,240 
#2 "bosentan" [Supplementary Concept] OR Bosentan OR "riociguat" 
[Supplementary Concept] OR riociguat 
2,352 
#3* randomized controlled trial [pt] OR controlled clinical trial [pt] OR 
randomized [tiab] OR placebo [tiab] OR drug therapy [sh] OR 
randomly [tiab] OR trial [tiab] OR groups [tiab] 
3,763,628 
#4 #1 AND #2 AND #3 69 
#5 Letter [pt] OR editorial[pt] OR review[pt]  3,374,162 
#6 animals [mh] NOT humans [mh] 4,188,108 
#7 #4 NOT #5 NOT #6: Filters: Humans, English 25 
* Adapted from Chapter 6: Searching for studies. In: Higgins JPT, Green S, editors. Cochrane 
handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The 
Cochrane Collaboration, 2011. 
Table 21. Embase via Embase.com 
Search Embase Search Algorithm Hits 
#1 'chronic thrombo embolic pulmonary hypertension'/exp OR 'chronic 
thrombo embolic pulmonary hypertension' OR cteph 
2,138 
#2 'bosentan'/exp OR 'riociguat'/exp 7,060 
#3** random* OR factorial OR crossover OR 'cross over' OR 'cross-over' OR 
placebo* OR (doubl* AND blind*) OR (singl* AND blind*) OR assign* 
OR allocate* OR volunteer* OR 'crossover-procedure'/exp OR 'double-
blind procedure'/exp OR 'randomized controlled trial'/exp OR 'single-
blind procedure'/exp 
1,851,990 
#5 #1 AND #2 AND #3 132 
#6 'letter':it OR 'editorial':it OR 'review':it  3,514,134 
#7 #3 NOT #4 AND [humans]/lim AND [english]/lim 72 
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** Adapted from Chapter 6: Searching for studies. In: Higgins JPT, Green S, editors. Cochrane 
handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The 
Cochrane Collaboration, 2011. 
 
Table 22. CENTRAL via Cochrane Library 
Search Cochrane Search Algorithm Hits 
#1 Chronic thromboembolic pulmonary hypertension 81 
#2 bosentan or riociguat 352 
#3 #1 AND #2 38 
#4 Cochrane Central Register of Controlled Trials : Issue 2 of 12, February 2016 31 
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APPENDIX B. PRISMA DIAGRAM 
Figure 8. Attrition diagram for Systematic Literature Review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 
2009;6(6):e1000097. doi:10.1371/journal.pmed1000097 
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APPENDIX C. MODEL PARAMETERS 
Table 23. Details of Distributions used in the Probabilistic Sensitivity Analysis 
Variable Distribution  Parameters  
effFCIV_Dist Beta subtype: 2, alpha: ((0.426^2)*(1-0.426)/(0.259^2)), beta: 
(0.426*(1-0.426)/(0.259^2))-((0.426^2)*(1-
0.426)/(0.259^2)) 
effFCIII_Dist Beta subtype: 2, alpha: ((0.630^2)*(1-0.630)/(0.259^2)), beta: 
(0.630*(1-0.630)/(0.259^2))-((0.630^2)*(1-
0.630)/(0.259^2)) 
effFCII_Dist Beta subtype: 2, alpha: ((0.705^2)*(1-0.705)/(0.205^2)), beta: 
(0.705*(1-0.705)/(0.205^2))-((0.705^2)*(1-
0.705)/(0.205^2)) 
pFCworsening_Dist Beta subtype: 2, alpha: (((0.12)^2)*(1-(0.12))/((0.012)^2)-
(0.12)), beta: ((1-(0.12))*(((1-(0.12))*(0.12))/((0.012)^2)-
1)) 
pFCimprovement_Dist Beta subtype: 2, alpha: (((0.10)^2)*(1-(0.10))/((0.01)^2)-(0.10)), 
beta: ((1-(0.10))*(((1-(0.10))*(0.10))/((0.01)^2)-1)) 
CostHospitalization_P
erEpis_Dist 
Gamma alpha: ((19216)^2)/((187677.5624)^2), lambda: 
(19216)/((187677.5624)^2) 
DrugCostBos_Dist Gamma alpha: 
(($184.98*2*30.42*3)^2)/((($184.98*2*30.42*3)^0.5)^2), 
lambda: 
($184.98*2*30.42*3)/((($184.98*2*30.42*3)^0.5)^2) 
DrugCostRio_Dist Gamma alpha: 
(($115.7311*3*30.42*3)^2)/((($115.7311*3*30.42*3)^0.5
)^2), lambda: 
($115.7311*3*30.42*3)/((($115.7311*3*30.42*3)^0.5)^2) 
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Table 24. Monte-Carlo Simulation Statistics (PSA) for Riociguat vs. Bosentan  
Attribute Statistics Bosentan Riociguat 
Cost Mean 2430595.53 2298424.12 
Cost Std Deviation 2789679.29 2789702.48 
Cost Minimum 2086803.68 1962474.98 
Cost 2.5% 2120533.13 1989019.99 
Cost 10% 2128434.22 1996553.65 
Cost Median 2143638.39 2011393.35 
Cost 90% 2163153.25 2030524.38 
Cost 97.5% 3620787.85 3480859.10 
Cost Maximum 151751798.29 151625266.70 
Cost Sum 243059553058.05 229842412017.84 
Cost Size (n) 100000.00 100000.00 
Cost Variance 7782310564216.58 7782439941943.00 
Cost Variance/Size 77823105.64 77824399.42 
Cost SQRT[Variance/Size] 8821.74 8821.81 
Effectiveness Mean 41.55* 42.16* 
Effectiveness Std Deviation 8.96 9.45 
Effectiveness Minimum 6.48 5.72 
Effectiveness 2.5% 21.93 21.27 
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Attribute Statistics Bosentan Riociguat 
Effectiveness 10% 28.99 28.79 
Effectiveness Median 42.60 43.41 
Effectiveness 90% 52.39 53.51 
Effectiveness 97.5% 55.75 56.73 
Effectiveness Maximum 60.66 61.10 
Effectiveness Sum 4154962.82 4216397.78 
Effectiveness Size (n) 100000.00 100000.00 
Effectiveness Variance 80.31 89.39 
Effectiveness Variance/Size 0.00 0.00 
Effectiveness SQRT[Variance/Size] 0.03 0.03 
Net Monetary Benefit Mean -353114.12 -190225.23 
Net Monetary Benefit Std Deviation 2824360.60 2828337.68 
Net Monetary Benefit Minimum -149104603.46 -148945367.91 
Net Monetary Benefit 2.5% -1654989.19 -1518037.65 
Net Monetary Benefit 10% -800442.22 -682884.19 
Net Monetary Benefit Median -38712.91 132159.92 
Net Monetary Benefit 90% 468024.23 656596.28 
Net Monetary Benefit 97.5% 640080.63 820848.65 
Net Monetary Benefit Maximum 906695.80 1048939.83 
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Attribute Statistics Bosentan Riociguat 
Net Monetary Benefit Sum -35311412087.34 -19022523211.58 
Net Monetary Benefit Size (n) 100000.00 100000.00 
Net Monetary Benefit Variance 7977012794655.19 7999494010076.36 
Net Monetary Benefit Variance/Size 79770127.95 79994940.10 
Net Monetary Benefit SQRT[Variance/Size] 8931.41 8943.99 
* Effectiveness values will be divided by 3 to obtain the QALYs, which will be 13.85, and 14.05 for 
Bosentan and Riociguat respectively. 
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